

CMP: ₹ 565

Target: ₹ 660 (17%) Target Period: 12 months

May 3, 2023

Strong growth in FY23 likely to sustain in FY24...

About the stock: Incorporated in 1992, Newgen is a low code application development platform company. It is an established player in the market of enterprise content management (ECM), business process management (BPM) & customer communications management (CCM).

- Annuity based revenues (SaaS + ATS/AMC + Support) comprise 61% of the revenue mix while license & others form 18.3% of the revenue mix each
- Vertical wise, BFSI comprises 66% of revenue mix while geographical break-up has been largely equal between India, US, EMEA & APAC

Q4FY23 Results: Newgen reported strong revenue numbers in Q4FY23.

- Revenue grew 31.9% YoY while SaaS revenue grew 66.6% YoY
- The company added 11 new logos in Q4
- Annuity revenue grew 32.4% YoY

What should investors do? Newgen's share price has grown ~2.3x over the past five years (from ~₹ 251 in May 2018 to ₹ 565 levels in May 2023).

• We maintain our **BUY** rating on the stock

Target Price and Valuation: We value Newgen at ₹ 660 i.e. 19x P/E on FY25E EPS.

Key triggers for future price performance:

- Strong logo addition and increasing annuity mix (recurring business) from existing clients would aid revenue growth of 20.9% CAGR in FY23-25E
- The company is targeting 10 deals per year as far as the GSI opportunity is concerned, which will drive incremental revenue opportunity
- Recent acquisition of number theory will strengthen its platform with Al/ML modelling and data analytics capability

Alternate Stock Idea: Apart from Newgen, in our IT coverage we also like Infosys.


- Key beneficiary of improved digital demand, double digit revenue growth and healthy capital allocation prompt us to be positive
- BUY with a target price of ₹ 1600



Particulars	
Particular	Amount
Market Cap (₹ Crore)	3,934
Total Debt	4.2
Cash and Invest (₹ Crore)	340
EV (₹ Crore)	3,599
52 week H/L	595/ 300
Equity capital	69.7
Face value	10.0

Shareho	lding pa	ttern		
	Jun-22	Sep-22	Dec-22	Mar-23
Promoter	55.2	55.4	55.2	55.2
FII	14.8	15.7	12.5	14.0
DII	6.8	7.0	8.1	8.2
Public	23.3	21.9	24.3	22.6

Price Chart



Nifty (L.H.S) — Price (R.H.S)

Recent event & key risks

- Added 47 new logos in FY23
- Key Risk: (i) Lower than expected revenues (ii) Lower than expected margins

Research Analyst

Sameer Pardikar sameer.pardikar@icicisecurities.com

Sujay Chavan sujay.chavan@icicisecurities.com

Key Financial Summary							
₹ Crore	FY21	FY22	FY23	5 Year CAGR (FY17-22)	FY24E	FY25E	2 Year CAGR (FY23-25E)
Net Sales	673	779	974	13.7	1,187	1,424	20.9
EBITDA	192	195	212	16.8	247	300	18.9
EBITDA Margins (%)	28.5	25.0	21.8		20.8	21.0	
Net Profit	126	164	176	19.3	206	247	18.4
EPS (₹)	18.1	23.5	25.0		28.9	34.7	
P/E	30.9	23.9	22.3		19.1	15.9	
RoNW (%)	19.0	20.2	18.0		17.9	18.2	
RoCE (%)	26.4	23.7	21.1		20.8	21.2	

Company Update

Key takeaways of recent quarter & conference call highlights

- The company reported revenue of ₹ 305.1 crore, up 31.9% YoY. Annuity revenue (ATS/AMC, SaaS & Support), forming 54.4% of the mix in Q4, was at ₹ 166.2 crore, up 32.4% YoY while license revenue was at 19.3% of the mix, up 39% YoY to ₹ 58.8 crore. The subscription revenue (ATS/AMC & SaaS that is 28.7% of mix), grew 25.5% YoY to ₹ 87.6 crore. SaaS revenue, 9.7% of mix, grew 66.6% YoY
- EBITDA margins increased ~850 bps sequentially and ~250 bps YoY to 31.6%
- Geography wise US region (24.6% of mix) continued its growth momentum from Q3FY23 and reported strong growth of 39.9% YoY. Indian region (28.4% of mix) and EMEA (35% of mix) grew 37.8% & 33.8% YoY, respectively, while the APAC region grew 4.2% YoY
- Vertical wise BFS (71% of mix) grew 39.7% YoY while the smaller verticals of healthcare, BPO/IT & insurance grew 84.5%, 31.8% & 17.2% YoY, respectively
- For FY23, the company reported a revenue of ₹ 974 crore, up 25%. EBITDA margin for FY23 declined 320 bps to 21.8% due to resumption of travel expenses and increase in sales & marketing expenses. Newgen, for FY23, reported PAT of ₹ 176.3 crore with a PAT margin of 18.1%. The company mentioned that in FY23 it incurred R&D expenses of ~10% of revenue
- The company reiterated it goal to reach US\$500 mn annual revenues in the medium term. Newgen mentioned that it posted strong growth of 25% in FY23, which was even higher than its guidance (of 20% + growth, given at the start of the year). The company mentioned that growth was aided not only by its traditional markets like India, EMEA & APAC but also by the US market where it is witnessing recovery. Newgen mentioned that this strong growth of FY23 is likely sustainable in FY24 as well. As far as AMEA region is concerned, the company mentioned that it is seeing some structural changes in the market wherein some markets like Saudi Arabia, UAE are now de-linking their strategy (of technology investments) from oil price movements. Hence, the region may see sustainable tech investments
- The company expects EBITDA margins in the range of 20-21% for FY24 & PAT margin of ~18% and mentioned that it is now looking to step up investments in terms of manpower, R&D, etc. Newgen also said that the cost base for the company is more realistic now as employee and travel costs started normalising, which, along with facility costs (99% of the workforce has started coming to office at least once in a week), will likely restrict margin expansion. The company also mentioned that EBITDA margin expansion may play out as in when it reaches US\$400 mn annual revenues
- The company mentioned that client additions in FY23 may look lower than
 its historical numbers as it has moved away from a few deals coming from
 its channel partners in some regions. Newgen also added that it is looking
 to accelerate logo additions in future by entering new geographies as well
 as acceleration of logo additions from its existing markets of Australia, US
 and Europe. The company also mentioned that it aims to win large deals at
 a similar or higher than the average deal size in coming years
- The company added that its product Newgen 1 & Trade Finance (which it launched 1.5 years ago) is witnessing increased demand and is also getting accreditation by Gartner & Forrester. Newgen added that its Trade Finance product is getting increased traction in the Middle East, India and US markets where it closed some marquee deals while some more deals are in the pipeline. Newgen also mentioned that the GTM strategy in trade finance is still being worked out in lending portfolio of some banks with annual revenues of more than US\$20 billion

👂 Company Update | Newgen Software

- On the US market, the company mentioned that its growth has picked up from Q3FY23 onwards. Newgen mentioned that its business is diversified in the US as it is looking to scale up both opportunities (organic as well as through GSI) for its growth ahead. The company added that scaling & winning logos with GSIs has not been at its expected pace so far but it expects the GSI momentum to pick up and likely contribute to revenue growth of the company
- The company mentioned that it is not seeing any systematic risk pertaining to the US market due to recent banks related issue there and expects growth in the region to continue. Newgen further added that its funnel in the US market remains strong and it is now looking to acquire clients within the revenue band of US\$50-100 bn
- The company mentioned that it has entered into strategic agreements with Mambu & Sopra to expand its geographical presence in Europe wherein Mambu & Sopra has a strong presence. Newgen mentioned that it will provide low code digital lending products to Sopra clients and core banking products with Mambu. The company said that partner ecosystem with Mambu & Sopra will aid in revenue growth of the company
- The company's clients with annual billing over ₹ 5 crore has increased from 38 to 51 indicating that the company strategy of client mining & upselling is helping to grow its revenues and also helping to reduce the client concentration
- Newgen for the first time reported the total bookings numbers. It reported a total bookings amount of ₹ 1,290.5 crore, up 29% YoY in Q4FY23
- On the R&D front, the company mentioned that since it is a product-based company R&D is core to its business and will continue to invest in R&D to enhance its services. Newgen mentioned that it will continue to invest 10% of revenue on R&D activities. The company also mentioned that compared to international competitors it enjoys cost advantage as it conduct its R&D activities in India
- On the recent tech development in generative AI, the company mentioned that since it is a product-based company it does not see generative AI as a threat for them compared to service-based IT companies. Newgen, however, mentioned that it will work to see how the generative AI will aid in its R&D activities and also mentioned tech disruption would provide an opportunity to develop new products in the areas of content management & document processing, which can increase productivity using AI
- The company mentioned that its DSO increased to 145 days in March, 2023 which is due to major billing done in the March quarter. Newgen added that it is working to bring the DSO to the levels of 120 days
- The company mentioned that its effective tax rate (ETR) for FY23 was at 18.9% and also indicated that it ETR will be at similar rate for the next two to three years
- The company declared a final dividend of ₹ 5 per share for FY23 and also mentioned that it has fixed June 20 as record date for determining the eligible shareholders for payment of dividend

Exhibit 1: P&L	Q4FY23	04EV22	YoY (%)	03EV22	QoQ (%)	Comments
	u+1123	U41122	101 (%)	uji 123	uuu (%)	
Revenue	305.1	231.4	31.8	254.9	19.7	SaaS revenue grew by 66.6% YoY and annuity based revenue 54.4% of mix grew by 32.4% YoY
Employee expense	141.5	111.2	27.3	130.4	8.5	
Gross Margin	163.5	120.2	36.0	124.5	31.3	
Gross margin (%)	53.6	51.9	166 bps	48.8	476 bps	
Other expense	67.1	52.8	27.1	65.6	2.2	
EBITDA	96.4	67.4	43.0	58.9	63.7	
EBITDA Margin (%)	31.6	29.1	248 bps	23.1	850 bps	Margins grew on YoY basis on operating leverage
Depreciation & amortisation	6.8	5.0	37.1	6.2	10.1	
EBIT	89.7	62.5	43.5	52.8	70.0	
EBIT Margin (%)	29.4	27.0	239 bps	20.7	870 bps	
Other income (less interest)	6.7	3.6	86.6	8.3	-19.5	
PBT	96.4	66.1	45.8	61.1	57.8	
Tax paid	17.7	8.7	104.6	12.9	37.9	
PAT	78.6	57.4	36.9	48.2	63.1	

Source: Company, ICICI Direct Research

	FY24E FY25E Comments				FY24E FY25E				
(₹ Crore)	Old	New	% Change	Old	New	% Change			
Revenue	1,112	1,187	6.7	1,304	1,424	9.2	Revenue re-aligned on management commentry on sustainable growth in FY24		
EBITDA	240	247	3.3	287	300	4.6			
EBITDA Margin (%)	21.5	20.8	-70 bps	22.0	21.0	-92 bps	We cut margins on planned increased in investments		
PAT	212	206	-3.1	248	247	-0.2			
EPS (₹)	30.4	28.9	-3.1	35.5	34.7	-0.2			

95.7

04FY23

38.4 32.4

Q4FY23

50.0

03FY23

33.4

02FY23

25.5

02FY23

24.3

03FY23

23.3

01FY23

26.6

01FY23

66.6


Key Metrics





Source: Company, ICICI Direct Research

Exhibit 5: Subscription revenue continues to grow strong



40.0 30.0 20.0 10.0 (2.0) 03FY21 (10.0)

(%)

04FY21

Exhibit 4: SaaS continues healthy growth

35.4

03FY22

Exhibit 6: ...which along with SaaS driving annuity growth

17.2

03FY22

11.0

04FY22

Annuity (SaaS+ ATS/AMC+ Subscription) Revenue growth YoY

9.1

SaaS Revenue growth YoY (%)

04FY22

28.9

02FY22

Q1FY22

20.3

01FY22

02FY22

4.7

31.0

19.2

04FY21

Source: Company, ICICI Direct Research

03FY21

120.0

100.0

80.0


60.0

40.0

20.0


50.0

Source: Company, ICICI Direct Research




Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research







New Client Addition

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

56.1 55.9

01FY22

54.7

Q3FY21

80.0

70.0

60.0

50.0

40.0

Exhibit 11: EMEA grows 33.8% YoY




Exhibit 13: US region showing recovery with 39.9% growth

54.8 53.6

03FY22


USA Region Revenue (in Crs)

48.9

02FY22

Source: Company, ICICI Direct Research

04FY21



Source: Company, ICICI Direct Research

04FY21

Source: Company, ICICI Direct Research

Exhibit 10: India revenue grows 37.9% YoY in Q4



35.2

04FY22

30.5

03FY22

APAC Region Revenue (in Crs)

Source: Company, ICICI Direct Research

32.4

24.2

03FY21

40.0

35.0

30.0

25.0

20.0

15.0

75.0

Q4FY23

62.2

03FY23

51.7

02FY23

46.0

01FY23

Q4FY22

Exhibit 12: APAC growth moderates to 4.2% YoY

23.9

02FY22

18.0

01FY22

ICICI Direct Research

36.0 36.7

04FY23

6


03FY23

33.3

02FY23

20.2

01FY23



Source: Company, ICICI Direct Research

Financial Summary

xhibit 17: Profit & loss st	tatement			(₹ cror
(Year-end March)	FY22	FY23	FY24E	FY25E
Total operating Income	779	974	1,187	1,424
Growth (%)	15.8	25.0	21.9	20.0
COGS (employee expenses)	409	516	643	771
Other expenses	175	246	297	354
Total Operating Expenditure	584	762	940	1,125
EBITDA	195	212	247	300
Growth (%)	1.4	9.0	16.6	21.2
Depreciation	18	25	29	30
Other income (net)	26	30	32	32
PBT	203	217	251	301
Total Tax	39	41	45	54
PAT	164	176	206	247
Growth (%)	29.8	7.3	16.7	20.2
Diluted EPS (₹)	23.5	25.0	28.9	34.7
Growth (%)	29.9	6.3	15.5	20.2

Exhibit 19: Balance Sheet				(₹ croi
(Year-end March)	FY22	FY23	FY24E	FY25E
Equity Capital	70	70	70	70
Reserve and Surplus	742	907	1,077	1,289
Total Shareholders funds	811	977	1,147	1,358
Total Debt	6	4	4	4
Lease liablity	15	28	28	28
Provisions	33	35	43	51
Other non current liabilties	4	3	-	-
Total Liabilities	870	1,048	1,222	1,442
Assets				
Property,plant and equipment	163	165	162	165
Goodwill	3	3	3	3
Intangibles	16	13	13	13
Right-of-use assets	48	64	55	46
Other non current assets	131	270	325	390
Cash & bank balance	276	208	292	370
Current Investments	92	131	131	131
Trade receivables	279	388	439	527
Unbilled revenue	-	-	-	_
Other financial assets	88	84	103	123
Other current assets	11	15	19	22
Total Current Assets	746	827	984	1,174
Trade payables	36	35	43	51
Lease liablity	7	10	10	10
OCL & provisions	194	249	267	287
Total Current Liabilities	237	294	320	348
Net Current Assets	509	533	664	826
Application of Funds	870	1,048	1,222	1,442

Source: Company, ICICI Direct Research

(Year-end March)	FY22	FY23	FY24E	FY25E
PBT	203	217	251	301
Add: Depreciation	18	25	29	30
Others	6	7	(32)	(32
Inc/(dec) in working capital	(36)	(73)	(94)	(140
Taxes paid	(48)	(40)	(45)	(54
CF from operating activities	143	136	108	105
(Inc)/dec in Fixed Assets	(13)	(17)	(20)	(24
Others	(68)	(78)	36	36
CF from investing activities	(81)	(94)	16	12
Dividend paid & dividend tax	(24)	(31)	(36)	(36
Others	(8)	(13)	(4)	(4
CF from financing activities	(32)	(44)	(40)	(40)
Net Cash flow	30	(2)	84	78
Exchange difference	2	6	-	-
Opening Cash	242	276	208	292
Closing cash & Bank	276	208	292	370

Source: Company, ICICI Direct Research

Exhibit 20: Key ratios				
(Year-end March)	FY22	FY23	FY24E	FY25E
Per share data (₹)				
Diluted EPS	23.5	25.0	28.9	34.7
Cash EPS	26.1	28.9	33.6	39.9
BV	117	140	165	195
DPS	4.5	5.0	5.1	5.1
Cash Per Share	40	30	42	53
Operating Ratios (%)				
EBITDA margin	25.0	21.8	20.8	21.0
PBT Margin	26.1	22.3	21.1	21.2
PAT Margin	21.1	18.1	17.3	17.4
Debtor days	131	145	135	135
Unbilled days	-	-	-	-
Creditor days	17	13	13	13
Return Ratios (%)				
RoE	20.2	18.0	17.9	18.2
RoCE	23.7	21.1	20.8	21.2
RolC	28.2	21.4	22.6	24.3
Valuation Ratios (x)				
P/E	23.9	22.3	19.1	15.9
EV / EBITDA	18.3	17.0	14.2	11.5
EV / Net Sales	4.6	3.7	3.0	2.4
Market Cap / Sales	5.1	4.0	3.3	2.8
Price to Book Value	4.8	4.0	3.4	2.9
Solvency Ratios				
Debt/EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	3.4	3.9	3.7	3.7
Quick Ratio	3.4	3.9	3.7	3.7

pankaj.pandey@icicisecurities.com

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Sameer Pardikar, MBA, Sujay Chavan, MMS, Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, TeI: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icciabank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.